Research programme: biosimilar monoclonal antibodies and protein therapeutics - Percivia
Latest Information Update: 20 Nov 2012
At a glance
- Originator PERCIVIA
- Class Monoclonal antibodies; Proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 07 Aug 2012 Discontinued for Undefined indication in Netherlands (Parenteral)
- 22 Sep 2010 Investigation in Undefined indication in Netherlands (Parenteral)